Cozopt sterile eye drops are indicated for the treatment of elevated intraocular pressure (IOP) in patients with:
It is used in patients whose elevated IOP is not sufficiently controlled with topical beta-blocker therapy alone.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cozopt contains dorzolamide hydrochloride and timolol maleate, which lower intraocular pressure through complementary mechanisms.
Dorzolamide is a human carbonic anhydrase II inhibitor. It reduces aqueous humour secretion by inhibiting carbonic anhydrase in the ciliary processes. This decreases the formation of bicarbonate ions and subsequently reduces sodium and fluid transport, resulting in reduced aqueous humour production.
Timolol is a non-selective beta-adrenergic receptor blocker. It has no significant intrinsic sympathomimetic activity, direct myocardial depressant activity, or local anaesthetic (membrane-stabilizing) activity. Timolol lowers intraocular pressure primarily by reducing the formation of aqueous humour in the ciliary epithelium.
The combined action of dorzolamide and timolol produces a greater reduction in intraocular pressure than either component used alone.
Instill 1 drop into the conjunctival sac of the affected eye(s) twice daily, or use exactly as prescribed by the ophthalmologist.
The safety and effectiveness of Cozopt in children below 2 years of age have not been established.
No clinically significant overall differences in safety or effectiveness have been observed between elderly patients and other adult patients.
Because timolol is a beta-blocker, patients with certain cardiovascular or respiratory conditions may require additional evaluation before treatment.
Cozopt may produce additive cardiovascular or systemic effects when used with certain medicines, including:
Concomitant use with systemic carbonic anhydrase inhibitors or other beta-blockers may increase systemic adverse effects.
CYP2D6 inhibitors, such as quinidine and some SSRIs, may increase systemic beta-blockade associated with timolol.
Patients should inform their doctor about all medicines, vitamins, and supplements they are taking before starting treatment.
There are no adequate and well-controlled studies of Cozopt in pregnant women. The medicine should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus, as determined by a healthcare professional.
Caution should be exercised when Cozopt is administered to breastfeeding mothers. The decision to use the medicine during lactation should be made by a healthcare professional after considering the potential benefits and risks.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.